# Advisor Review - GPT-5.2

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5.2
**Paper:** paper.pdf
**Timestamp:** 2026-02-23T18:05:16.871931
**Route:** OpenRouter + LaTeX
**Paper Hash:** 4c57b70b488c7229
**Tokens:** 15630 in / 1987 out
**Response SHA256:** e41ed54b1b6f84bc

---

FATAL ERROR 1: Internal Consistency (CRITICAL)
  Location: Section 5 “Identification in Practice” (Control group limitations) vs. Table 1 “Summary Statistics” (\Cref{tab:summary}) and the paragraph immediately after it
  Error: The paper states: “Only Bihar and Assam—comprising 35 mandis—never received e-NAM during our sample period.” But Table 1 reports “Never-Treated Mandis” of only 4 (onion) + 2 (tomato) + 0 (wheat) + 0 (soyabean) = 6 never-treated mandis in the regression sample, and the text below Table 1 emphasizes the near-absence of never-treated units. These two descriptions of the never-treated control group size are contradictory, and the size/availability of never-treated controls is central to the feasibility/interpretation of staggered DiD (especially long-run effects).
  How to fix:
   - Recompute and report the actual count of never-treated mandis *in the regression sample* (after the ≥60-month filter), by commodity and overall.
   - If “35 mandis” refers to the raw (pre-filter) dataset, explicitly say so and do not describe them as available controls for the estimating sample.
   - Ensure every place describing the control group (Introduction/Data/Empirical Strategy/Identification in Practice/Limitations) uses the same numbers for the *estimation sample*.

FATAL ERROR 2: Data–Design Alignment (CRITICAL: post-treatment identification feasibility)
  Location: Event-study interpretation in Section 6.2 (“rise to approximately 5–7 percent by the third year”) + the design description in Section 5 (CS-DiD uses not-yet-treated controls; treatment cohorts concentrated 2016–2018) + treatment cohort list in Data Section 4.3 (last main cohort is March 2018; only a small Phase 2 in May 2020 for a few UTs)
  Error: Your preferred CS-DiD is described as using “not-yet-treated mandis as controls.” But your rollout schedule implies that (for the main Phase 1 states) essentially everyone is treated by March 2018. If wheat/soybean have **no never-treated mandis in the regression sample** (Table 1 shows 0 for both) and if there are **no materially later-treated wheat/soybean units with usable panel length**, then for horizons like “third year post-treatment” for the April 2016 cohort (i.e., 2019), there may be *no not-yet-treated controls left*, making those long-horizon CS-DiD event-study coefficients non-identifiable. In that case, statements about effects by the “third year” (and any post-2018 dynamic path) would be based on periods where the required comparison group does not exist.
  How to fix:
   - Explicitly document, for wheat and soyabean, the distribution of first-treatment dates in the *analysis sample* (counts of mandis by cohort/treatment quarter/year), and show that there are still not-yet-treated units available at each event time you plot/interpret.
   - If after 2018 there are no valid not-yet-treated (or never-treated) controls for wheat/soy, then:
     * truncate the CS-DiD event-study to the last period where controls exist, and
     * remove/qualify claims about “third year” (and any longer-run dynamics).
   - Alternatively, if you truly have later-treated wheat/soy mandis (e.g., Phase 2 in 2020) in the estimation sample, you must state this clearly and reconcile it with Table 1 (which currently suggests essentially full treatment and no never-treated for those commodities).

ADVISOR VERDICT: FAIL